Clinic Roundup

February 2011
BioWorld Today;2/11/2011, Vol. 22 Issue 29, p2
This section offers news briefs on drug trials. A Phase II trial is being conducted by Diamyd Medical AB for its NP2 Enkephalin drug for the reduction of cancer pain. Enrollment in a Phase I trial of therapeutic caner vaccine DPX-0907 has been completed by Immunovaccine Inc. A Phase II trial of oral taxane tesetaxel has been initiated by Genta Inc. for the treatment of advanced prostate cancer.


Related Articles

  • Diamyd Stock Plunges 85% on Phase III Diabetes Miss. Sheridan, Cormac // BioWorld Today;5/10/2011, Vol. 22 Issue 90, p1 

    The article reports that share price in Diamyd AB dropped by 85 percent following news that its immunotherapy treatment for Type I diabetes called Diamyd failed to reach the primary endpoint of a European Phase III trial. Diamyd is a therapeutic vaccine that is a recombinant type of glutamic...

  • Diamyd Completes Recruitment In Gene Therapy Pain Trial. Sheridan, Cormac // BioWorld International;5/23/2012, p2 

    The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after...

  • Diamyd Medical Reports Results from Phase II Study in Cancer Pain.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that the drug NP2 Enkephalin developed by Diamyd Medical AB did not meet its primary objective of reducing pain in cancer patients. NP2 Enkephalin is based on the Medical's patented Nerve Targeting Drug Delivery System (NTDDS) platform and delivers the natural painkilling...

  • Diamyd Medical's Phase II study in cancer pain fully recruited.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article presents information on the Diamyd Medical AB which has recruited the last patient for the treatment of cancer pain with the drug candidate NP2 Enkephalin. It informs that this clinical trial is the first placebo-controlled clinical trial of a drug candidate. As per Peter Zerhouni,...

  • Investigational Drug Helps Men with Advanced PCa.  // Renal & Urology News;Nov2010, Vol. 9 Issue 11, p32 

    The article offers information on the findings of the phase three study regarding the effect of the investigational agent called abiraterone acetate to men with advanced metastatic prostate cancer (PCa) which was presented at the 35th Annual European Society for Medical Oncology Congress wherein...

  • Enrollment begins for nationwide prostate cancer trial.  // Geriatrics;Dec93, Vol. 48 Issue 12, p23 

    Reports on the enrollment of patients for a large-scale, nationwide prevention trial for prostate cancer sponsored by the National Cancer Institute.

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • Clinic Roundup.  // BioWorld Today;5/23/2012, p5 

    This section offers news briefs on clinical trials. A Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron to treat peritumoral brain edema associated with cerebral tumors has been completed by Celtic Pharmaceutical Holdings LP....

  • Abiraterone Improves Survival in Prostate Cancer Phase III. Moran, Nuala // BioWorld International;9/15/2010, Vol. 15 Issue 36, p3 

    The article reports on the shares increase posted by London, England-based pharmaceutical company BTG plc to 2.27 British pounds, after it has revealed Phase III study on Abiraterone for treatment of prostrate cancer. It mentions that the company has invested in pre-clinical work and was able to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics